Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 309

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 309
---
 times the respective loan amount divided by 75% of the lowest price per
Ordinary Share during the first five trading days following the consummation of this offering, at an exercise price equal to 75% of
the lowest price per Ordinary Share during the first five trading days following the consummation of this offering. The outstanding
debt will become immediately due and payable upon an event of default (as defined in the December 2024 Loan Agreement), which shall
be deemed to have occurred upon certain circumstances as detailed in the December 2024 Loan Agreement. On March 31, 2025, we and our
Chief Executive Officer entered an amendment to the December 2024 Loan Agreement to extend the maturity date until the earlier of
August 31, 2025, and during September 2025, the December 2024 Loan Agreement was further extended to November 30, 2025, or the
consummation of an IPO. On July 1, 2025, we entered into an amendment to the December 2024 Loan Agreement such that our Chief
Executive Officer shall be granted warrants to purchase up to 55,224 Ordinary Shares following the consummation of this public
offering.

In April 2025, we
entered into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained a bridge loans in the aggregate
amount of $200,000 from certain lenders, including certain related parties. The loans pursuant to the 2025 Loan Agreements bear
interest at a rate of 8% per annum until maturity. Pursuant to the terms of the 2025 Loan Agreements, we also agreed to pay the
lenders an additional risk premium equal to 50% of their respective loan amount. The loans under the 2025 Loan Agreements mature
upon the earlier of August 31, 2025, and during September 2025, the 2025 Loan Agreements were further extended to November 30, 2025,
or the date of consummation of a Qualified IPO. Furthermore, upon the occurrence of a Qualified IPO, the Bridge Loan lenders, shall
be granted warrants to purchase such number of Ordinary Shares equal to 92,309 Ordinary Shares following the consummation of this
offering.

The sales of the above securities
were deemed to be exempt from registration under the Securities Act because they were made outside of the United States of America to
certain non-U.S. individuals